Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 4/12/2020
SIETES contiene 93177 citas

 
 
 1 a 20 de 36 siguiente >>
Presentar resultados
Seleccionar todas
1.
Moser M, Setaro JF. Resistant of difficult-to-control hypertension. N Engl J Med 2006;355:385-92. [Ref.ID 77769]
2.
Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, Tanaka K, Ohkubo K, Nakamura H, Abe I, Fujishima M, Iida M. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly. Arch Intern Med 2003;163:361-6. [Ref.ID 64993]
3.
Clause SL, Hamilton RA. Medicaid prescriber compliance with Joint National Committee VI Hypertension Treatment Guidelines. Ann Pharmacother 2002;36:1505-11. [Ref.ID 63527]
4. Cita con resumen
Bonet A, Gosalbes V, Fito M, Navarro J. Prescripción racional y reducción de costes en el tratamiento de la hipertensión arterial: un ejercicio de simulación. Gac Sanit (Barc) 2001;15:327-35. [Ref.ID 61789]
5.Tiene citas relacionadas
Parving H H, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Investigators. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. The authors reply. N Engl J Med 2002;346:707. [Ref.ID 60504]
6.Tiene citas relacionadas
Brenner BM, for the RENAAL Study investigators. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. The authors reply. N Engl J Med 2002;346:706-7. [Ref.ID 60503]
7.Tiene citas relacionadas
8.Tiene citas relacionadas
Walser M. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med 2002;346:706. [Ref.ID 60501]
9.Tiene citas relacionadas
Ceriello A, Motz E. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med 2002;346:705-6. [Ref.ID 60500]
10.Tiene citas relacionadas
Blankfield RP. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med 2002;346:705. [Ref.ID 60499]
12.Tiene citas relacionadas
Hyman DJ, Pavlik V. Other factors in self-reported hypertension treatment practices among primary care physicians. In reply. Arch Intern Med 2001;161:1458. [Ref.ID 57282]
13.Tiene citas relacionadas
Vasandani G. Other factors in self-reported hypertension treatment practices among primary care physicians. Arch Intern Med 2001;161:1458. [Ref.ID 57281]
14. Cita con resumen
Bradbury J. Better control of systolic blood pressure called for in USA. Lancet 2000;355:1700. [Ref.ID 50955]
15. Cita con resumen
Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Lancet 2000;355:863-4. [Ref.ID 49882]
16.Tiene citas relacionadas Cita con resumen
Chaturvedi N. HOPE and extension of the indications for ACE inhibitors?. Lancet 2000;355:246-7. [Ref.ID 49016]
17. Cita con resumen
Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 1999;58:579-87. [Ref.ID 47419]
18.Tiene citas relacionadas
Sastre García F, García Bernabé C, López Reinoso C, Arribas Mir L. ¿Y la espironolactona en el tratamiento de la insuficiencia cardíaca?. Aten Primaria 2000;25:281-2. [Ref.ID 47229]
19.Tiene citas relacionadas
O'Brien E, Staessen JA. What is hypertension?. Lancet 1999;354:594. [Ref.ID 46531]
20.Tiene citas relacionadas
Murray S, James MA. What is hypertension?. Lancet 1999;354:593-4. [Ref.ID 46530]
Seleccionar todas
 
 1 a 20 de 36 siguiente >>